- The Weed Blog https://www.theweedblog.com

Double-Blind Scientific Tests Of Marijuana Exist Despite Prohibitionist Propaganda

6
Share.

marijuana science research cannabisOften medical marijuana foes will use certain claims to support the position that cannabis has no proven medical benefits. One of the frequently-used claims is that there are no double-blind, placebo-controlled studies showing marijuana’s medicinal benefits. The University of California’s Center for Medical Cannabis Research has produced studies that meet that criteria and support the medical properties of cannabis.

www.cmcr.ucsd.edu/index.php?option=com_content&view=category&id=41&Itemid=135

The CMCR lists 13 scientific papers on their Completed Studies page, including these two:

 

Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy  

INVESTIGATOR: Ronald Ellis, M.D., Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy

PROJECT TYPE: Clinical Study

STATUS: COMPLETE

RESULTS:

Of 127 volunteers screened, 34 eligible subjects enrolled and 28 completed both cannabis and placebo treatments. Among completers, pain relief was greater with cannabis than placebo (median difference in DDS pain intensity change, 3.3 points, effect size = 0.60; p = 0.016). The proportions of subjects achieving at least 30% pain relief with cannabis versus placebo were 0.46 [95% CI 0.28, 0.65] and 0.18 [0.03, 0.32]. Mood and daily functioning improved to a similar extent during both treatment periods. Although most side effects were mild and self-limited, two subjects experienced treatment-limiting toxicities.

Smoked cannabis was generally well-tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV DSPN.

The full results of this study were published in the journal Neuropsychopharmacology.

Their second study:

A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effects of Smoked Marijuana on Subjects with Neuropathic Pain; Correlation with Changes in Mood, Cognition, and Psychomotor Performance

INVESTIGATOR: Barth Wilsey, M.D.

STUDY LOCATION: University of California, Davis

PROJECT TITLE: A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effects of Smoked Marijuana on Subjects with Neuropathic Pain; Correlation with Changes in Mood, Cognition, and Psychomotor Performance

PROJECT TYPE: Clinical Study

STATUS: COMPLETE

RESULTS:

Thirty-eight patients with central and peripheral neuropathic pain underwent a standardized procedure for smoking either high-dose (7%), low-dose (3.5%) or placebo cannabis. In addition to the primary outcome of pain intensity, secondary outcome measures included evoked pain using heat-pain threshold, sensitivity to light touch, psychoactive side-effects, and neuropsychological performance. A mixed linear model demonstrated an analgesic response to smoking cannabis. No effect on evoked pain was seen. Psychoactive effects were minimal and well-tolerated, with some acute cognitive effects, particularly with memory, at higher doses.

The full results of this study have been published in the Journal of Pain.

 

Beyond these two studies, other institutes of higher learning have been generating scientific papers about human trials related to the effects of cannabis.

From the Journal of Clinical Oncology:

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

 

From the Multiple Sclerosis Journal:

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

 

From the Journal of Cannabis Therapeutics:

A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of CannabisBased Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)

Source: The Compassion Chronicles

Share.

About Author

"Rick Thompson was the Editor in Chief for the entire 2-year run of the Michigan Medical Marijuana Magazine, was the spokesman for the Michigan Association of Compassion Centers and is the current Editor and Lead Blogger for The Compassion Chronicles. Rick has addressed committees in both the House and Senate, has authored over 200 articles on marijuana and is a professional photographer." Rick Thompson Is An Author At The Compassion Chronicles and focuses on all things Michigan.